Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

PegBio 派格生物 IPO: PHIP Updates Don’t Look Good

PegBio 派格生物 Pre-IPO: R&D Deceleration

PegBio 派格生物 IPO: A Hardsell but Mostly Done Deal

PegBio 派格生物 IPO: A (Supposedly) Straightforward GLP-1 Challenger Story

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<ul>
<li>PegBio, a China-based biotech company, plans to raise up to USD 150 million via a Hong Kong listing.</li>
<li>In our previous note, we examined the company’s core product namely PB-119.</li>
<li>In this note, we will provide a valuation for the company’s key products.</li>
</ul>


PegBio, a China-based biotech company, plans to raise up to USD 150 million via a Hong Kong listing.
In our previous note, we examined the company’s core product namely PB-119.
In this note, we will provide a valuation for the company’s key products.


PegBio (派格生物) IPO: Thoughts on Valuation